Cordlife Group Ltd. is a healthcare company focused on providing integrated stem cell banking and diagnostics services. The primary function of Cordlife is to offer families a reliable choice for preserving their newborn's umbilical cord blood, which is a rich source of hematopoietic stem cells used in various medical treatments. The company also extends its services to include diagnostic tests and tools that serve the healthcare industry. This includes genetic testing which helps in the early identification of potential health issues, showcasing its role in preventive healthcare.

Cordlife's operations emphasize the enhancement of human health through advanced biological resources management. By strategically positioning itself in multiple countries across Asia, the company plays a significant part in the biotech industry, particularly in regions with burgeoning demands for advanced medical technologies. The company's commitment to innovation and quality service makes it a key player in the biomedical field, offering vital services that support medical research, therapeutic advancements, and overall healthcare solutions. As a publicly listed entity, it has attained a noteworthy presence in the market, underlining its importance in the domain of life sciences and medical services.